Reply to: "sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue"

Journal of Hepatology

Volumn 60, Issue 3, 2014, Pages 682-683

  Sposito, Carlo ^a   Mazzaferro, Vincenzo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMAN; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84894104564     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.10.032     Document Type: Letter

References (5)

1. C. Sposito, L. Mariani, A. Germini, R.M. Flores, M. Bongini, and G. Grossi et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study J Hepatol 59 2013 59 66
2. C. Zavaglia, A. Airoldi, A. Mancuso, M. Vangeli, R. Vigano, and G. Cordone et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature Eur J Gastroenterol Hepatol 25 2013 180 186
3. K. Staufer, L. Fischer, B. Seegers, E. Vettorazzi, B. Nashan, and M. Sterneck High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation Transpl Int 25 2012 1158 1164
4. C. Toso, G. Mentha, and P. Majno Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence J Hepatol 59 2013 3 5
5. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829